Daré Bioscience Announces Publication Of Phase 2b Study Efficacy Results Of Topical Sildenafil Cream, 3.6% For The Treatment Of Female Sexual Arousal Disorder In Obstetrics & Gynecology
Daré Bioscience Announces Publication Of Phase 2b Study Efficacy Results Of Topical Sildenafil Cream, 3.6% For The Treatment Of Female Sexual Arousal Disorder In Obstetrics & Gynecology
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
2b期研究表明，3.6%局部用西地那非乳膏可改善女性性喚起障礙（FSAD）的療效，特別是在一部分帶有或不帶有同時存在降低性慾的FSAD女性中表現更佳。
There are currently no FDA-approved therapies for FSAD
目前尚無FDA批准的FSAD治療方法。
SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced the publication in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists (ACOG), of the Phase 2b study efficacy results of topical Sildenafil Cream 3.6% (Sildenafil Cream), which is being developed for the treatment of female sexual arousal disorder (FSAD).
2024年6月24日聖地亞哥，全球新聞通訊社（GLOBE NEWSWIRE）——Dare生物科技公司（NASDAQ:DARE）是女性健康和幸福的創新領袖，今天宣佈在《產科和婦產學》（Obstetrics & Gynecology)上發表了局部用3.6%西地那非乳膏（西地那非乳膏）2b期研究療效結果。該藥正在開發用於治療女性性喚起障礙（FSAD）的療法。《產科和婦產學》該2b期臨床研究是一項探索性、多中心、雙盲、安慰劑對照研究，旨在評估3.6%局部用西地那非乳膏在絕經前FSAD患者中的初步療效和安全性。局部用西地那非乳膏改善了FSAD女性的療效，尤其是在一部分患有或不患有同時降低性慾的女性中療效最顯著的一項探索性後續分析表明，局部用西地那非乳膏顯著提高了性喚起感覺，並減輕了性困擾，改善了性慾和性高潮。
The Phase 2b clinical study was designed as an exploratory, multi-center, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with FSAD. Topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm.
該2b期臨床研究是一項探索性、多中心、雙盲、安慰劑對照研究，旨在評估3.6%局部用西地那非乳膏在絕經前FSAD患者中的初步療效和安全性。局部用西地那非乳膏改善了FSAD女性的療效，尤其是在一部分患有或不患有同時降低性慾的女性中療效最顯著的一項探索性後續分析表明，局部用西地那非乳膏顯著提高了性喚起感覺，並減輕了性困擾，改善了性慾和性高潮。
譯文內容由第三人軟體翻譯。